HeartSciences annual gross margin
2022
2023
2024
2025
HeartSciences's gross margin was 56.78% for fiscal 2025.
View full HeartSciences company overview| Fiscal year | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-04-30 | 56.78% | −10.52 pp |
| 2024 | 2024-04-30 | 67.31% | +21.60 pp |
| 2023 | 2023-04-30 | 45.71% | +0.60 pp |
| 2022 | 2022-04-30 | 45.11% | — |
| Fiscal quarter | Period ended | Gross margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2025-10-31 | 58.33% | −2.70 pp |
| Q1 2026 | 2025-07-31 | 60.00% | +23.63 pp |
| Q3 2024 | 2024-01-31 | 68.97% | −0.18 pp |
| Q2 2024 | 2023-10-31 | 61.03% | −7.81 pp |
| Q3 2023 | 2023-01-31 | 61.03% | +37.94 pp |
| Q1 2023 | 2022-07-31 | 36.38% | — |
| Q4 2022 | 2022-04-30 | 69.15% | — |
| Q3 2022 | 2022-01-31 | 68.83% | — |
| Q1 2022 | 2021-07-31 | 23.09% | — |
Across the available reported history, HeartSciences's gross margin decreased from 67.31% to 56.78%, a change of −10.52 percentage points. The latest reported quarter, Q2 2026, shows 58.33%.
Gross margin measures the percentage of revenue remaining after the direct costs of producing goods or services. It helps show how efficiently a company turns sales into gross profit before operating expenses.
TickerStat calculates gross margin as SEC-reported gross profit divided by SEC-reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review HeartSciences filings at SEC.gov ↗